Phathom Pharmaceuticals, Inc. Total Assets

Total Assets of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Total Assets growth rates and interactive chart. Total assets are the sum of all current and noncurrent assets and must equal the sum of total liabilities and stockholders' equity combined. In the accounting industry, assets are defined as anything that a business owns, has value, and can be converted to cash.


Highlights and Quick Summary

  • Total Assets for the quarter ending September 29, 2021 was $228 Million (a 6.43% increase compared to previous quarter)
  • Year-over-year quarterly Total Assets decreased by -22.61%
  • Annual Total Assets for 2020 was $295 Million (a 14.75% increase from previous year)
  • Annual Total Assets for 2019 was $257 Million (a 28411.97% increase from previous year)
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Total Assets of Phathom Pharmaceuticals, Inc.

Most recent Total Assetsof PHAT including historical data for past 10 years.

Interactive Chart of Total Assets of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Total Assets for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $228.38 $214.58 $246.36
2020 $295.11 $230.89 $252.42 $263.92 $295.11
2019 $257.18 $79.71 $0.0 $0.0 $257.18
2018 $0.0 $0.0 $0.9

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.